Aviragen Therapeutics (AVIR) Misses Q4 EPS Views
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.18), $0.43 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $60 thousand versus the consensus estimate of $21 million.
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Gold (ABX) Tops Q3 EPS by 4c
- CryoLife (CRY) Tops Q3 EPS by 8c, Boosts FY Guidance
- Newmarket (NEU) Tops Q3 EPS by 81c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!